Tricida Announces Proposed Public Offering of Common Stock
- Dow, S&P post worst week in months after hawkish Fed spooks investors
- Fed-fueled dollar rises as bears make for exits
- Adobe (ADBE) Edges Higher After Topping Q2 Estimates, Analysts Raise PT on 'Impressive' Performance
- Fed Statement Very Bullish for Tech Stocks, Focus on Cloud and Cyber Stocks - Wedbush
- You Fight Real Physical Inflation With Rate Hikes, Not Talk of Rate Hikes; Buy the Dip in Commodities, Gold Underpriced - Goldman Sachs
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by Tricida. In addition, Tricida expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager.
A registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.
The offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailingĀ email@example.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, or by emailingĀ firstname.lastname@example.org; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, or facsimile: 631-254-7140.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD) by binding and removing acid from the gastrointestinal tract.
Jackie Cossmon, IRC
Vice President of Investor Relations and Communications
Source: Tricida, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SEC to close tomorrow in observance of Juneteenth
- SK-II Studio(TM) Returns with Film "BEYOND THE STADIUM" in Support of Women Entrepreneurs in Tokyo Who Are Fighting to Keep Their Dreams Alive
- Xinhua Silk Road: Shanghai holds hi-tech films and television city press conference to spur city's construction
Create E-mail Alert Related CategoriesPress Releases
Related EntitiesJPMorgan, Goldman Sachs, Needham & Company, Cowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!